Stockscreener 앱 받기
1.50
4.17%
0.06
전일 마감가:
$1.44
열려 있는:
$1.42
하루 거래량:
600.56K
Relative Volume:
0.42
시가총액:
$242.92M
수익:
-
순이익/손실:
$-274.18M
주가수익비율:
-0.5918
EPS:
-2.5346
순현금흐름:
$-198.33M
1주 성능:
-9.64%
1개월 성능:
+16.28%
6개월 성능:
-11.76%
1년 성능:
-86.56%
1일 변동 폭
$1.39
$1.54
1주일 범위
$1.39
$1.6994
52주 변동 폭
$0.611
$17.19
Neumora Therapeutics Inc Stock (NMRA) Company Profile
명칭
Neumora Therapeutics Inc
전화
(857) 760-0900
주소
260 ARSENAL PLACE, SUITE 1, WATERTOWN
NMRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
1.50 | 233.20M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-02 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2025-03-10 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-10-01 | 개시 | H.C. Wainwright | Buy |
| 2024-07-22 | 개시 | Needham | Buy |
| 2024-07-08 | 개시 | Mizuho | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Hold |
| 2023-10-10 | 개시 | BofA Securities | Buy |
| 2023-10-10 | 개시 | Guggenheim | Buy |
| 2023-10-10 | 개시 | JP Morgan | Overweight |
| 2023-10-10 | 개시 | RBC Capital Mkts | Outperform |
| 2023-10-10 | 개시 | Stifel | Buy |
| 2023-10-10 | 개시 | William Blair | Outperform |
모두보기
Neumora Therapeutics Inc 주식(NMRA)의 최신 뉴스
Federated Hermes Inc. Invests $285,000 in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
William Blair Has Positive Estimate for NMRA FY2029 Earnings - MarketBeat
Neumora's Q2 2025 Earnings Call: Unpacking Key Contradictions in M4 PAM Safety, Obesity Focus, and KOASTAL Studies - AInvest
Q3 EPS Estimate for Neumora Therapeutics Boosted by Analyst - MarketBeat
Neumora Therapeutics reports Q2 EPS (33c), consensus (37c) - MSN
Elevidys sales weaken; Neumora gets into obesity - BioPharma Dive
Neumora Therapeutics Faces Challenges as It Transitions to Full Public Company Compliance - TipRanks
Neumora Therapeutics’ Earnings Call Highlights Promising Pipeline - TipRanks
Neumora outlines six upcoming clinical catalysts and prioritizes obesity program with NMRA-215 - MSN
Stifel maintains Hold rating on Neumora Therapeutics stock at $2.00 By Investing.com - Investing.com Canada
Promising Developments and Pipeline Progress Drive Buy Rating for Neumora Therapeutics - TipRanks
Neumora Therapeutics, Inc.: Promising Potential in Obesity Therapeutics with NMRA-215 - TipRanks
Earnings call transcript: Neumora Therapeutics beats Q2 2025 EPS estimates - Investing.com
Neumora Therapeutics Reports Q2 2025 Financial Results - TipRanks
Neumora Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Neumora Targets $180B Obesity Market with New Brain-Penetrant Drug, Reports 6 Clinical Readouts Coming - Stock Titan
Neumora Therapeutics to Report Q2 2025 Financial Results on August 6, 2025 - AInvest
Neumora Therapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
How volatile is Neumora Therapeutics Inc. stock compared to the marketUnprecedented market success - Jammu Links News
Why is Neumora Therapeutics Inc. stock attracting strong analyst attentionSignificant capital appreciation - Jammu Links News
Does Neumora Therapeutics Inc. stock perform well during market downturnsCapitalize on fast-growing stocks today - Jammu Links News
How does Neumora Therapeutics Inc. generate profit in a changing economyCapitalize on market trends with expert guidance - Jammu Links News
Is it the right time to buy Neumora Therapeutics Inc. stockFree Trading Psychology Coaching - Jammu Links News
What institutional investors are buying Neumora Therapeutics Inc. stockAchieve triple-digit returns with smart investing - Jammu Links News
What are the latest earnings results for Neumora Therapeutics Inc.Capitalize on market momentum for maximum profit - Jammu Links News
What are analysts’ price targets for Neumora Therapeutics Inc. in the next 12 monthsAI Powered Tips With High Returns - Jammu Links News
Neumora Therapeutics (NMRA) Projected to Post Earnings on Wednesday - MarketBeat
How strong is Neumora Therapeutics Inc. company’s balance sheetExpert Picks Entry Points For 2025 - Jammu Links News
What is the dividend policy of Neumora Therapeutics Inc. stockPost Market Planner That Work - Jammu Links News
How many analysts rate Neumora Therapeutics Inc. as a “Buy”Chart Pattern Updates For Fast Growth - Jammu Links News
What are the technical indicators suggesting about Neumora Therapeutics Inc.Chart Pattern Guidance To Watch Now - Jammu Links News
Key metrics from Neumora Therapeutics Inc.’s quarterly dataTrade Insight With Community Collaboration Supported - metal.it
What are Neumora Therapeutics Inc. company’s key revenue driversAI Powered Planner Backed By Experts - Jammu Links News
Why Neumora Therapeutics Inc. stock attracts strong analyst attentionStrong Buy With Technical Confidence Supported - beatles.ru
Published on: 2025-07-30 12:15:41 - metal.it
Mizuho Raises Price Target for Neumora (NMRA), Keeps Outperform Rating - MSN
Mizuho Boosts Neumora Price Target to $5, Maintains Outperform Rating - AInvest
Pegasystems Delivers Strong Q2 Results, Raises Price Target to $58 - AInvest
Published on: 2025-07-29 01:24:00 - metal.it
What is Neumora Therapeutics Inc. company’s growth strategyNavigate market volatility with smart strategies - jammulinksnews.com
When is Neumora Therapeutics Inc. stock expected to show significant growthCapitalize on market trends with expert guidance - Jammu Links News
Neumora Therapeutics Inc (NMRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.91%
3.06%
자본화:
|
볼륨(24시간):